This content was made for video and podcast format:
Last month Teladoc (#TDOC) reported Q1 earnings and investors were not impressed. The technology health company announced Q1 GAAP EPS of -$1.31 (misses by $0.72) and revenue of $453.68M (+150.9% Y/Y).
Revenue did increase dramatically for the Y/Y, but the company gave stagnant growth numbers for Q2, which is not what bullish investors wanted to see for a growth stock. With weak guidance dragging the stock down, is now the time for investors to buy #Teladoc stock on the dip?